Advertisement

Treatment of Co-occurring Alcohol, Drug, and Psychiatric Disorders

  • Jack R. Cornelius
  • Duncan B. Clark
  • Oscar G. Bukstein
  • Ihsan M. Salloum
Chapter
Part of the Recent Developments in Alcoholism book series (RDIA, volume 17)

Abstract

Comorbid psychiatric disorders and drug use disorders (DUDs) are common among adolescents with alcohol use disorders (AUDs). These comorbid disorders have a large potential significance on the clinical course of the AUDs among adolescents, and can predict a shorter time to relapse of alcohol use. The use of medication for treatment of the various comorbid adolescent populations has increased dramatically in recent years, despite the lack of double-blind, placebo-controlled studies that demonstrate their safety and efficacy. Consequently, to date, no empirically proven treatment exists for most of these comorbid disorders. This chapter reviews the state of the art regarding the treatment of comorbid adolescents. This chapter also identifies gaps in knowledge regarding the treatment of comorbid adolescents, and outlines directions for future research in this field.

Keywords

Attention Deficit Hyperactivity Disorder Anxiety Disorder Major Depression Alcohol Dependence Conduct Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Apsler, R. (1994). Is drug abuse treatment effective? American Enterprise March/April, 46–53.Google Scholar
  2. Armentano, M.E., & Solhkhah, R. (2003). Co-occurring disorders in adolescents, In Principles of Addiction Medicine, Third Ed, Section 13, Chapter 8, pp. 1573–1584, 2003.Google Scholar
  3. Birmaher, B., Brent, D.A., Kolko, D., Baugher, M., Bridge, J., Holder, D., Iyengar, S., & Uloa, R.E. (2000). Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Archives of General Psychiatry 57, 29–36.CrossRefPubMedGoogle Scholar
  4. Birmaher, B., Axelson, D.A., Monk, K., Kalas, C., Clark, D.B., Ehmann, M., Bridge, J., Heo, J., & Brent, D.A. (2003). Flouxetine for the treatment of childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry 42, 415–423.PubMedGoogle Scholar
  5. Brady, K.T., Halligan, P., & Malcolm, R.J. (1999). Dual diagnosis. In M. Galanter & H.D. Kleber (Eds.), Textbook of Substance Abuse Treatment, 2nd ed., Washington, DC: The American Psychiatric Press, pp. 475–483.Google Scholar
  6. Bukstein, O.G., & Cornelius, J. (in press). Psychopharmacology of adolescents with substance use disorders: using diagnostic specific treatments. In H. Liddle & C. Rowe (Eds.) Treating Adolescent Substance Abuse: State of the Science.Google Scholar
  7. Bukstein, O.G., & Kaminer, Y. (1994). The nosology of adolescent substance abuse and dependence. Alcohol Health and Research World 18, 296–301.Google Scholar
  8. Cannabis Youth Treatment (CYT) Group (2000). Cannabis youth treatment (CYT) experiment: preliminary findings. A report presented to the Center for Substance Abuse Treatment (CSAT). U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Rockville, MD.Google Scholar
  9. Christie, K.A., Burke, J.D., Regier, D.A., Rae, D.S., Bod, J.H., & Locke, B.Z. (1988). Epidemiologic evidence for early onset of mental disorders and higher risk of drug abuse in young adults. American Journal of Psychiatry 145, 971–975.PubMedGoogle Scholar
  10. Clark, D.B., Bukstein, O., & Cornelius, J. (2002). Alcohol use disorders in adolescents: epidemiology, diagnosis, psychosocial interventions, and pharmacological treatment. Pediatric Drugs 4, 493–502.PubMedGoogle Scholar
  11. Clark, D.B., Bukstein, O.G., Smith, M.G., Kaczynski, N.A., Mezzich, A.C., & Donovan, J.E. (1995). Identifying anxiety disorders in adolescents hospitalized for alcohol abuse or dependence. Psychiatric Services 46, 618–620.PubMedGoogle Scholar
  12. Clark, D.B., Lesnick, L., & Hegedus, A.M. (1997). Traumas and other adverse events in adolescents with alcohol abuse or dependence. Journal of the American Academy of Child and Adolescent Psychiatry 36, 1744–1751.CrossRefPubMedGoogle Scholar
  13. Clark, D.B., Pollock, N.K., Bukstein, O.G., Mezzich, A.C., Bromberger, J.T., & Donovan, J.E. (1997). Gender and comorbid psychopathology in adolescents with alcohol dependence. Journal of the American Academy of Child and Adolescent Psychiatry 36, 1195–1203.CrossRefPubMedGoogle Scholar
  14. Clark, D.B, Vanyukov, M., & Cornelius, J. (2002). Childhood antisocial behavior and adolescent alcohol use disorders. Alcohol Research and Health 26, 109–115.Google Scholar
  15. Clark, D.B., Wood, D.S., Cornelius, J.R., Bukstein, O.G., & Martin, C.S. (2003). Clinical practices in the pharmacological treatment of comorbid psychopathology in adolescents with alcohol use disorders. Journal of Substance Abuse Treatment. 25:293–295.CrossRefPubMedGoogle Scholar
  16. Corby, E.A., Roll, J.M., Ledgerwood, D.M., & Schuster, C.R. (2000). Contingency management interventions for treating the substance abuse of adolescents: a feasibility study. Experimental Clinical Psychopharmacology 8, 371–376.CrossRefGoogle Scholar
  17. Cornelius, J.R., Bukstein, O.G., Birmaher, I.M., Salloum, I.M., Kelly, T.M., Walters, M.C., Wood, S.D., & Clark, D.B. (2003). Fluoxetine in depressed AUD adolescents: a three-year follow-up evaluation. Alcoholism: Clinical and Experimental Research 27(5) Suppl. 145A.Google Scholar
  18. Cornelius, J.R., Bukstein, O.G., Birmaher, B., Salloum, I.M., Lynch, K., Pollock, N.K., Gershon, S., & Clark, D.B. (2001). Fluoxetine in adolescents with major depression and an alcohol use disorder: An open label trial. Addictive Behaviors 26, 735–739.CrossRefPubMedGoogle Scholar
  19. Cornelius, J.R., Bukstein, O.G., Salloum, I.M., Kelly, T.M, Wood, D.S., & Clark, D.B. (2004). Fluoxetine in depressed AUD adolescents: a one-year follow-up evaluation. Journal of Child and Adolescent Psychopharmacology. 14:35–40.CrossRefGoogle Scholar
  20. Cornelius, J.R., Maisto, S.A., Martin, C.S., Bukstein, O.G., Salloum, I.M., Daley, D.C., Wood, D.S., & Clark, D.B. (2004). Major depression associated with earlier alcohol relapse in treated teens with AUD. Addictive Behaviors. 29:1035–1038.CrossRefPubMedGoogle Scholar
  21. Deas, D., Riggs, P., Langenbucher, J., Goldman, M., & Brown, S. (2000). Adolescents are not adults: developmental considerations in alcohol users. Alcoholism: Clinical and Experimental Research 24, 232–237.CrossRefGoogle Scholar
  22. Deas, D., & Thomas, S.E. (2001). An overview of controlled studies of adolescent substance abuse treatment. The American Journal on Addictions 10, 178–189.CrossRefPubMedGoogle Scholar
  23. Deas-Nesmith, D., Randall, C., Roberts, J., & Anton, R. (1998). Sertraline treatment of depressed adolescent alcoholics: a pilot study. Alcoholism: Clinical and Experimental Research 22, 74A.Google Scholar
  24. Dishion, T.J., McCord, J., & Poulin, F. (1999). When interventions harm: Peer groups and problem behavior. American Psychologist 54(4), 755–764.CrossRefPubMedGoogle Scholar
  25. Emslie, G.J. (2002). Second controlled study finds efficacy of fluoxetine in pediatric depression. Brown University Child and Adolescent Psychopharmacology Update 4(12) 1–3.Google Scholar
  26. Emslie, G.J., Rush, A.J., Weinberg, W.A., Kowatch, R.A., Hughes, C.W., Carmody, T., & Rintelmann, J. (1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry 54, 1031–1037.PubMedGoogle Scholar
  27. Emslie, G.J., Rush, A.J., Weinberg, W.A., Kowatch, R.A., Carmody, T., & Mayes, T.L. (1998). Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depression and Anxiety 7, 32–39.CrossRefPubMedGoogle Scholar
  28. Eyre, S.L., Rounsaville, B.J., & Kleber, H.D. (1982). History of childhood hyperactivity in a clinic population of opiate addicts. Journal of Nervous and Mental Disorders 170, 522–529.Google Scholar
  29. Fleming, J.E., & Offord, D.R. (1990). Epidemiology of childhood depressive disorders: a critical review. Journal of the American Academy of Child and Adolescent Psychiatry 29, 571–580.PubMedGoogle Scholar
  30. Food and Drug Administration (FDA) Approvals (2003). Fluoxetine Supplemental NDA. Medscape Pharmacists 4(1), 2.Google Scholar
  31. Food and Drug Administration (2004). Worsening depression and suicidality in patients being treated with antidepressant medications. http:/ /www.fda.gov/cder/drug/antidepressants/default.htmGoogle Scholar
  32. Geller, B., Cooper, T.B., Sun, K., Zimerman, B., Frazier, J., Williams, M., & Heath, J. (1999). Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. Journal of the American Academy of Child and Adolescent Psychiatry 37, 171–178.CrossRefGoogle Scholar
  33. Greenfield, S.F., Weiss, R.D., Muenz, L.R., Vagge, L.M., Kelly, J.F., Bello, L.R., & Michael, J. (1998). The effect of depression on return to drinking. Archives of General Psychiatry 55, 259–265.CrossRefPubMedGoogle Scholar
  34. Hazell, P., O'Connell, D., Heathcote, D., Robertson, J., & Henry, D. (1995). Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. British Medical Journal 310, 897–901.PubMedGoogle Scholar
  35. Henggeler, S.W., Clingempeel, W.G., Brondino, M.J., & Pickrel, S.G. (2002). Four-year follow-up of multisystemic therapy with substance-abusing and substance-dependent juvenile offenders. Journal of the American Academy of Child and Adolescent Psychiatry 41, 868–874.CrossRefPubMedGoogle Scholar
  36. Hesselbrock, M.N., Meyer, R.E., & Keener, J.J. (1985). Psychopathology in hospitalized alcoholics. Archives of General Psychiatry 42, 1050–1055.PubMedGoogle Scholar
  37. Hird, S., Khuri, E.T., Dusenbury, L., & Millman, R.B. (1997). Adolescents. In J.H. Lowinson, P. Ruiz, R.B. Milman, & J.G. Langrod (Eds.) Substance Abuse: A Comprehensive Textbook 3rd ed., Williams & Wilkins, Baltimore, pp. 683–692.Google Scholar
  38. Hser, Y.I., Grella, C.E., Hubbard, R.L., Hsieh, S.C., Fletcher, B.W., Brown, B.S., & Anglin, D. (2001). An evaluation of drug treatments for adolescents in 4 US cities. Archives of General Psychiatry 58, 689–695.CrossRefPubMedGoogle Scholar
  39. Hubbard, R.L., Cavanaugh, E.R., Craddock, S.G., & Rachal, J.V. (1985). Characteristics, behaviors, and outcomes for youth in the TOPS. In A.S. Friedman & G. Beschner (Eds.), Treatment Services for Adolescent Substance Abusers, Rockville, MD: U.S. Department of Health and Human Services, pp. 49–65.Google Scholar
  40. Kaminer, Y. (1994). Understanding and Treating Adolescent Substance Abuse. New York: Plenum Press.Google Scholar
  41. Kaminer, Y. (1995). Pharmacotherapy for adolescents with psychoactive substance use disorders. In E. Rahdert & D. Czechowicz (Eds.), National Institute of Drug Abuse Research Monograph 156, Adolescent Drug Abuse: Clinical Assessment and Therapeutic Interventions, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Rockville, MD, pp. 291–324.Google Scholar
  42. Kaminer, Y. (2002). Adolescent substance abuse treatment: evidence-based practice in outpatient services. Current Psychiatry Reports 4, 397–401.PubMedGoogle Scholar
  43. Kaminer, Y., Burleson, J.A., Blitz, C., Sussman, J., & Rounsaville, B.J. (1998). Psychotherapies for adolescent substance abusers: a pilot study. Journal of Nervous and Mental Disorders 186, 684–690.CrossRefGoogle Scholar
  44. Kandel, D.B., Johnson, J.G., Bird, H.R, Canino G., Goodman, S.H., Lahey, B.B., Regier, D.A., & Schwab-Stone, M. (1997). Psychiatric disorders associated with substance use among children and adolescents: findings from the methods for the epidemiology of child and adolescent mental disorders (MECA) study. Journal of Abnormal Child Psychology 25, 121–132.CrossRefPubMedGoogle Scholar
  45. Keller, M.B., Ryan, N.D., Strober, M., Klein, R.G., Stan, K., Birmaher, B., Hagino, O., Koplewicz, H., Carlson, G., Clarke, G., Emslie, G., Feinberg, D., Geller, B., Kusumakar, V., Papatheodoro, G., Wagner, K.D., Weller, E.B., Winters, N.C., Oakes, R., & McCafferty, J.P. (2001). Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 40, 762–772.CrossRefPubMedGoogle Scholar
  46. Kessler, R.C., Crum, R.M., Warner, L.A., Nelson, C.B., Schulenberg, J., & Anthony, J.C. (1997). Life-time co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry 54, 313–321.PubMedGoogle Scholar
  47. Kessler, R.C., McGonagle, K.A., Zhao, S., Nelson, C.B., Hughes, M., Eshleman, S., Wittchen, H.U., & Kendler, K.S. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 51, 8–19.PubMedGoogle Scholar
  48. Kessler, R.C., & Walters, E.E. (1998). Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the national comorbidity survey. Depression and Anxiety 7, 3–14.CrossRefPubMedGoogle Scholar
  49. Khantzian, E.J. (1983). An extreme case of cocaine dependence and marked improvement with methylphenidate treatment. American Journal of Psychiatry 140, 784–785.PubMedGoogle Scholar
  50. King, G.R., & Ellinwood, E.H. (1997). Amphetamines and other stimulants. In J.H. Lowinson, P. Ruiz, R.B. Milman, & J.G. Langrod (Eds.) Substance Abuse: A Comprehensive Textbook 3rd ed. Baltimore: Williams & Wilkins, pp. 207–223.Google Scholar
  51. Klein, R.G., & Mannuzza, S. (1991). Long-term outcome of hyperactive children: a review. Journal of the American Academy of Child and Adolescent Psychiatry 30, 383–387.PubMedGoogle Scholar
  52. Kroenke, K, West, S.L., Swindle, R., Gilsenan, A., Eckert, G.J., Dolor, R., Stang, P., Zhou, X., Hays, R., & Weinberger, M. (2001). Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. Journal of the American Medical Association 286, 2947–2955.CrossRefPubMedGoogle Scholar
  53. Kuperman, S., Schlosser, S.S., Kramer, J.R., Bucholz, K., Hesselbrock, V., Reich, T., & Reich, W. (2001). Developmental sequence from disruptive behavior diagnosis to adolescent alcohol dependence. American Journal of Psychiatry 158, 2022–2026.CrossRefPubMedGoogle Scholar
  54. Levin, F.R., Sullivan, M.A., Donovan, S.J. (2003). Co-occurring addictive and attention deficit/hyperactivity disorder and eating disorder. In A.W. Graham, T.K. Schultz, M.F. Mayo-Smith, R.K. Ries, & B.B. Wilford (Eds.), Principles of Addiction Medicine, Third Edition, American Society of Addiction Medicine, Inc., Chevy Chase, MD, pp. 1321–1346.Google Scholar
  55. Lewis, D.O (1996). Conduct disorder. In M. Lewis (Ed.), Child and Adolescent Psychiatry: A Comprehensive Textbook, Second Edition, Williams & Wilkins, Baltimore, MD, pp. 564–574.Google Scholar
  56. Litten, R.Z., & Allen, J.P. (1995). Pharmacotherapy for alcoholics with collateral depression or anxiety: An update of research findings. Experimental and Clinical Psychopharmacology 3, 87–93.CrossRefGoogle Scholar
  57. Liddle, H.A., Dakof, G.A., Parker, K., Diamond, G.S., Barrett, K., & Jejeda, M. (2001). Multidimensional family therapy for adolescent drug abuse: results of a randomized clinical trial. American Journal of Drug and Alcohol Abuse 27, 651–687.CrossRefPubMedGoogle Scholar
  58. Mannuzza, S., & Klein, R.G. (2000). Long-term prognosis in attention-deficit/hyperactivity disorder. Child and Adolescent Psychiatric Clinics of North America 9(3), 711–726.PubMedGoogle Scholar
  59. Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, ER., Spencer, T., & The Atomoxetine ADHD Study Group (2001). Atomoxetine in the treatment of children and adolescents with ADHD: a randomized, placebo-controlled, dose-response study. Pediatrics 108, e83.CrossRefPubMedGoogle Scholar
  60. Miller, W.R., Zweben, A., DiClemente, C.C., & Rychtarik, R.G. (1992). Motivational Enhancement Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence. NIAAA Project MATCH Monograph Series, Volume 2, Editor: Margaret E. Mattson, Ph.D., U.S. Department of Health and Human Services, Public Health Service, NIH.Google Scholar
  61. National Opinion Research Center (1997). National Treatment Improvement Evaluation Study, Final Report. Rockville, MD: Center for Substance Abuse and Treatment, US Department of Health and Human Services.Google Scholar
  62. Pendergast, M.., Podus, D., Chang, E., & Urada, D. (2002). The effectiveness of drug abuse treatment: A meta-analysis of comparison group studies. Drug and Alcohol Dependence 67, 53–72.CrossRefGoogle Scholar
  63. Poulin, F., Dishion, T.J, & Burraston, B. (2001). 3-year iatrogenic effects associated with aggregating high-risk adolescents in cognitive-behavioral preventive interventions. Applied Development Science 5(4), 214–224.CrossRefGoogle Scholar
  64. Regier, D.A., Farmer, M.E., Rae, D.E., Locke, B.Z., Keith, E.J., Judd, L.L., & Goodwin, F.K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. Journal of the American Medical Association 264, 2511–2518.CrossRefPubMedGoogle Scholar
  65. Riggs, P.D., Mikulich, S.K., Coffman, L.M., & Crowley, T.J. (1997). Fluoxetine in drug-dependent delinquents with major depression: An open trial. Journal of Child and Adolescent Psychopharmacology 7, 87–95.PubMedCrossRefGoogle Scholar
  66. Riggs, P.D., Mikulich, S.K., & Hall, S.K. (2001). Effects of pemoline on ADHD, antisocial behaviors, and substance use in adolescents with conduct disorder and substance use disorder. Drug and Alcohol Dependence 63, S131.CrossRefGoogle Scholar
  67. Rohde, P., Lewinsohn, P.M., & Seeley, J.R. (1991). Comorbidity of unipolar depression: II. Comorbidity with other mental disorders in adolescents and adults. Journal of Abnormal Psychology 100, 214–221.CrossRefPubMedGoogle Scholar
  68. Rosack, J. (2003). FDA warns of suicide risk with paroxetine. Psychiatric News 38,1, 37.Google Scholar
  69. Sells, S.B., & Simpson, D.D. (1979). Evaluation of treatment outcome for youths in the Drug-Abuse Reporting Program (DARP): a follow-up study. In G.M. Beschner & A.S. Friedman (eds.) Youth Drug Abuse: Problems, Issues, and Treatment. Lexington Books, Lexington, MA, pp. 571–628.Google Scholar
  70. Szatmari, P. (1992). The epidemiology of attention deficit hyperactivity disorder. In G. Weiss (ed.) Child and Adolescent Psychiatric Clinics of North America. Philadelphia, PA: W.B. Saunders, pp. 361–384.Google Scholar
  71. Szatmari, P., Offord, D.R., & Boyle, M.N. (1989). Ontario child health study: Prevalence of attention deficit disorder with hyperactivity. Journal of Child Psychology and Psychiatry 30, 205–218.PubMedGoogle Scholar
  72. Varley, C.K., (2001). Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms, and clinical implications. Paediatric Drugs 3, 613–627.CrossRefPubMedGoogle Scholar
  73. Wagner, E.F., Brown, S.A., Monti, P.M., Myers, M.G., & Waldron, H.B. (1999). Innovations in adolescent substance abuse intervention. Alcoholism: Clinical and Experimental Research 23, 236–249.Google Scholar
  74. Wagner, K.D., Ambrosini, P., Rynn, M., Wohlberg, C., Yang, R., Greenbaum, M.S., Childress, A., Donnelly, C., & Deas, D. (2003). Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder. Journal of the American Medical Association 290, 1033–1041.CrossRefPubMedGoogle Scholar
  75. Waldron, H.B., Slesnick, N., Turner, C.W., Brody, J.L., & Peterson, T.R. (2001). Treatment outcomes for adolescent substance abuse at 4-and 7-month assessments. Journal of Consulting and Clinical Psychology 69, 802–813.CrossRefPubMedGoogle Scholar
  76. Weiss, G. (1996). Attention deficit hyperactivity disorder. In M. Lewis (ed.) Child and Adolescent Psychiatry: A Comprehensive Textbook, 2nd Ed. Baltimore: Williams & Wilkins, pp. 544–563.Google Scholar
  77. Winters, K.C., Stinchfield, R.D., & Opland, E. (2000). The effectiveness of the Minnesota Model approach in the treatment of adolescent drug abusers. Addiction 95, 601–612.CrossRefPubMedGoogle Scholar
  78. Wood, D., Wender, P.H., & Reimherr, F.W. (1983). The prevalence of attention deficit disorder, residual type, or minimal drain dysfunction, in a population of male alcoholic patients. American Journal of Psychiatry l40, 95–98.Google Scholar
  79. Zito, J.M., Safer, D.J., DosReis, S., Gardner, J.F., Soeken, K., Boles, M., & Lynch, F. (2002). Rising prevalence of antidepressants among US youth. Pediatrics 109, 721–727.CrossRefPubMedGoogle Scholar
  80. Zito, J.M., Safer, D.J., DosReis, S., Gardner, J.F., Magder, L., Soeken, K., Boles, M., Lynch, F., & Little, M.A. (2003). Psychotropic practice patterns for youth: a 10-year perspective. Archives of Pediatric and Adolescent Medicine 157, 17–25.Google Scholar

Copyright information

© Kluwer Academic/Plenum Publishers 2005

Authors and Affiliations

  • Jack R. Cornelius
    • 1
  • Duncan B. Clark
    • 1
  • Oscar G. Bukstein
    • 1
  • Ihsan M. Salloum
    • 1
  1. 1.School of MedicineUniversity of PittsburghPittsburgh

Personalised recommendations